(Q38026511)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22798030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

title

Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22798030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22798030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

Wai Yew Kong

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22798030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Ramyasuda Swaminathan

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22798030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

publication date

15 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22798030%20AND%20SRC:MED&resulttype=core&format=json

International Urology and Nephrology

8 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22798030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22798030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22798030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

795-802

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22798030%20AND%20SRC:MED&resulttype=core&format=json

Rituximab and nephrotic syndrome: a new therapeutic hope?

8 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0206-0

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0206-0

Rituximab: mechanisms and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0206-0

Minimal change nephropathy and focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0206-0

Pathogenesis of lipoid nephrosis: a disorder of T-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0206-0

Minimal change disease as a modifiable podocyte paracrine disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0206-0

Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0206-0

Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0206-0

Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0206-0

Rituximab induces regression of hepatitis C virus-related membranoproliferative glomerulonephritis in a renal allograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0206-0

Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0206-0

Tolerability and safety of rituximab (MabThera).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0206-0

Titrating Rituximab to Circulating B Cells to Optimize Lymphocytolytic Therapy in Idiopathic Membranous Nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0206-0

Rituximab for Idiopathic Membranous Nephropathy: Who Can Benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0206-0

Combined T- and B-cell activation in childhood steroid-sensitive nephrotic syndrome

21 January 2018

1 reference

12 December 2020

Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases

1 reference

12 December 2020

Rituximab in adult patients with immunosuppressive-dependent minimal change disease

1 reference

12 December 2020

Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment

1 reference

12 December 2020

Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab

1 reference

12 December 2020

Rituximab in patients with the steroid-resistant nephrotic syndrome

1 reference

12 December 2020

Remission of a B cell CLL-associated membranoproliferative glomerulonephritis Type I with rituximab and bendamustine

1 reference

12 December 2020

10.1007/S11255-012-0206-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22798030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference